Details for New Drug Application (NDA): 204616

NDA 204616 describes OXALIPLATIN, which is a drug marketed by Accord Hlthcare, Actavis, Actavis Totowa, Am Regent, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Oncol, Fresenius Kabi Usa, Gland, Gland Pharma Ltd, Hengrui Pharma, Hospira Inc, Hospira Worldwide, Meitheal, Mylan Labs Ltd, Norvium Bioscience, Novast Labs, Qilu Pharm Hainan, Sandoz, Sun Pharm, and Teva Pharms, and is included in twenty-seven NDAs. It is available from eighteen suppliers. Additional details are available on the OXALIPLATIN profile page.

The generic ingredient in OXALIPLATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.

Summary for 204616

Tradename:	OXALIPLATIN
Applicant:	Qilu Pharm Hainan
Ingredient:	oxaliplatin
Patents:	0

Pharmacology for NDA: 204616

Suppliers and Packaging for NDA: 204616

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	204616	ANDA	Qilu Pharmaceutical Co., Ltd.	67184-0501	67184-0501-1	1 VIAL, SINGLE-DOSE in 1 CARTON (67184-0501-1) / 10 mL in 1 VIAL, SINGLE-DOSE
OXALIPLATIN	oxaliplatin	INJECTABLE;INTRAVENOUS	204616	ANDA	Qilu Pharmaceutical Co., Ltd.	67184-0502	67184-0502-1	1 VIAL, SINGLE-DOSE in 1 CARTON (67184-0502-1) / 20 mL in 1 VIAL, SINGLE-DOSE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	50MG/VIAL
Approval Date:	May 11, 2016	TE:	AP	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	INJECTABLE;INTRAVENOUS			Strength	100MG/VIAL
Approval Date:	May 11, 2016	TE:	AP	RLD:	No

Complete Access Available with Subscription